22 completed. 22 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 22 | Completed 22 |
| Phase 1 | 2 | Completed 2 |
Follow Frontotemporal Lobar Degeneration: new trials by email Literature Review of Frontotemporal Lobar Degeneration trials Research Report on Frontotemporal Lobar Degeneration
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 2a Study of TPN-101 in Patients With C9ORF72 ALS/FTD TPN-101, 400 mg/day, Placebo - Amyotrophic Lateral Sclerosis, Frontotemporal Dementia | Phase 2 | Completed | Transposon Therapeutics, Inc. | 42 | 2021-10-01 | 2026-04-03 |
| A Study of LY3372689 to Assess the Safety, Tolerability, and Efficacy in Participants With Alzheimer's Disease LY3372689, Placebo - Alzheimer Disease | Phase 2 | Completed | Eli Lilly and Company | 327 | 2021-09-16 | 2026-06-12 |
| Dopaminergic Therapy for Frontotemporal Dementia Patients Rotigotine 4Mg/24Hrs Patch, Rotigotine 6Mg/24Hrs Patch, Placebo - Frontotemporal Dementia, Dementia | Phase 2 | Completed | I.R.C.C.S. Fondazione Santa Lucia | 75 | 2021-06-03 | 2024-10-22 |
| A Phase 2 Study to Evaluate Safety of Long-term AL001 Dosing in Frontotemporal Dementia (FTD) Patients (INFRONT-2) AL001 - Frontotemporal Dementia | Phase 2 | Completed | Alector Inc. | 33 | 2019-09-27 | 2025-12-05 |
| Palmitoylethanolamide Combined With Luteoline in Frontotemporal Dementia Patients. A Randomized Controlled Trial PEA-LUT, PLACEBO - Frontotemporal Dementia | Phase 2 | Completed | I.R.C.C.S. Fondazione Santa Lucia | 50 | 2019-06-01 | 2024-11-07 |
| Therapy in Amyotrophic Lateral Sclerosis (TAME) Memantine, Placebo (for Memantine) - Amyotrophic Lateral Sclerosis, Frontal Temporal Dementia | Phase 2 | Completed | University of Kansas Medical Center | 89 | 2018-11-07 | 2022-11-29 |
| Pathophysiology of Neurodegeneration in Late-life Depression (AV45+THK) F-18 AV-45, F-18-THK-5351 - Major Depressive Disorder | Phase 2 | Completed | Chang Gung Memorial Hospital | 59 | 2018-03-23 | 2022-01-26 |
| Blood Brain Barrier Opening in Alzheimer' Disease SONOCLOUD® - Alzheimer Disease | Phase 1 / Phase 2 | Completed | Assistance Publique - Hôpitaux de Paris | 10 | 2017-06-26 | 2022-04-12 |
| Low-Dose Lithium for the Treatment of Behavioral Symptoms in Frontotemporal Dementia Lithium Carbonate, Placebo - Frontotemporal Dementia (FTD) | Phase 2 | Completed | Columbia University | 17 | 2017-01-27 | 2025-02-03 |
| A Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Participants With Early Alzheimer's Disease ABBV-8E12, placebo for ABBV-8E12 - Alzheimer's Disease | Phase 2 | Completed | AbbVie | 453 | 2017-01-26 | 2022-08-26 |
| Tau PET Imaging With 18F-AV-1451 in Subjects With MAPT Mutations 18F-AV-1451 - Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD) | Phase 2 | Completed | Columbia University | 7 | 2016-04-01 | 2019-12-06 |
| 24 Months Safety and Efficacy Study of AADvac1 in Patients With Mild Alzheimer's Disease AADvac1, Placebo - Alzheimer's Disease | Phase 2 | Completed | Axon Neuroscience SE | 208 | 2016-03-01 | 2019-11-14 |
| [18F]THK-5351 Positron Emission Computed Tomography Study of Normal, Mild Cognitive Impairment, Alzheimer's Disease and Other Neurodegenerative Disease [18F]THK-5351 - Alzheimer's Disease, Mild Cognitive Impairment | Phase 2 | Completed | Jae Seung Kim | 135 | 2016-01-11 | 2020-12-14 |
| Tau Imaging of Chronic Traumatic Encephalopathy [F18]-T807, [F18]-Florbetapir, MRI/MRS - Chronic Traumatic Encephalopathy | Phase 2 | Completed | Brigham and Women's Hospital | 30 | 2015-01-01 | 2018-05-17 |
| Impact of Emotional Mimicry and Oxytocin on Frontotemporal Dementia Intranasal oxytocin, Saline Nasal Mist - Frontotemporal Dementia | Phase 2 | Completed | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 52 | 2013-09-12 | 2018-08-08 |
| Imaging Characteristics of Florbetapir 18F in Patients With Frontotemporal Dementia, Alzheimer's Disease and Normal Controls. florbetapir 18F, 18F-FDG - Alzheimer's Disease, Frontotemporal Dementia | Phase 2 | Completed | Avid Radiopharmaceuticals | 34 | 2009-09-01 | 2014-09-29 |
| A Pilot Trial of Lithium in Subjects With Progressive Supranuclear Palsy or Corticobasal Degeneration Lithium - Progressive Supranuclear Palsy, Corticobasal Degeneration | Phase 1 / Phase 2 | Completed | Westat | 17 | 2008-09-01 | 2024-05-17 |
| Effects of Tolcapone on Frontotemporal Dementia Tolcapone, Placebo - Frontotemporal Lobar Degeneration | Phase 2 | Completed | Columbia University | 28 | 2008-01-30 | 2024-08-28 |
| Efficacy and Tolerability of Memantine in Frontotemporal Dementia (FTD) Patients memantine - Dementia | Phase 2 | Completed | Nantes University Hospital | 52 | 2005-09-01 | 2026-09-14 |
| Double Blind Trial of DC Polarization in FTD Anodal DC polarization of left prefrontal cortex - Dementia | Phase 2 | Completed | National Institute of Neurological Disorders and Stroke (NINDS) | 20 | 2005-06-28 | 2017-07-02 |
Showing 20 of 22. Sign in to see all of them.
Frontotemporal Dementia (15) · Pick Disease of the Brain (10) · Alzheimer Disease (7) · Dementia (5) · Cognitive Dysfunction (3) · Neurodegenerative Diseases (3) · Plaque, Amyloid (3) · Tauopathies (3) · Amyotrophic Lateral Sclerosis (2) · Nerve Degeneration (2) · Nervous System Diseases (2) · Aphasia (1) · Aphasia, Primary Progressive (1) · Behavior (1)
Brain Diseases (21) · Central Nervous System Diseases (21) · Mental Disorders (21) · Neurocognitive Disorders (21) · Nervous System Diseases (20) · Neurodegenerative Diseases (19) · Dementia (17) · Nutritional and Metabolic Diseases (16) · Metabolic Diseases (15) · Proteostasis Deficiencies (15) · TDP-43 Proteinopathies (15) · Pathological Conditions, Signs and Symptoms (8) · Frontotemporal Dementia (7) · Tauopathies (6)
florbetapir (3) · 7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole (2) · Lithium (2) · Memantine (2) · Sugars (2) · AADvac1 (1) · Diffusion Tensor Imaging (1) · Fluorodeoxyglucose F18 (1) · Galantamine (1) · Genetic Testing (1) · Lithium Carbonate (1) · Magnetic Resonance Imaging (1) · Magnetic Resonance Spectroscopy (1) · Oxytocin (1) · THK5351 (1)
Columbia University (3) · I.R.C.C.S. Fondazione Santa Lucia (2) · National Institute of Neurological Disorders and Stroke (NINDS) (2) · AbbVie (1) · Alector Inc. (1) · Assistance Publique - Hôpitaux de Paris (1) · Avid Radiopharmaceuticals (1) · Axon Neuroscience SE (1) · Brigham and Women's Hospital (1) · Chang Gung Memorial Hospital (1) · Eli Lilly and Company (1) · Jae Seung Kim (1) · Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1) · Nantes University Hospital (1)
United States (12) · Canada (4) · Italy (4) · France (3) · Germany (3) · United Kingdom (3) · Australia (2) · Belgium (2) · Netherlands (2) · Poland (2) · Spain (2) · Sweden (2) · Austria (1) · Czechia (1) · Denmark (1)
Edward Huey, MD (3) · Alessandro Martorana, MD, PhD (1) · Anne Sophie Rigaud, MD (1) · Bernard Laurent, MD (1) · Bernard-Francois Michel, MD (1) · Bruno Dubois, MD (1) · Catherine Thomas-Anterion, MD (1) · Derek Mitchell, PhD (1) · Elizabeth C Finger, M.D. (1) · Francois Sellal, MD (1) · Giacomo Koch, MD (1) · Herve Allain, MD (1)
PMID 21157021, PMID 22922703, PMID 31834916, PMID 32963103, PMID 34815790, PMID 35184428, PMID 35260178, PMID 39580468, PMID 40368603, PMID 40809903, PMID 41281734, PMID 42441396
2016 (2), 2015 (1), R00NS060766 (1), R01NS076837 (1)